65081-42-7

Upstream product

• 858784-79-9 N-methyl-N-(5-methyl-2-nitro-phenyl)-hydrazine 
• 64-17-5 ethanol 
• 610-39-9 3,4-Dinitrotoluene 
• 74-89-5 methylamine 
• 38512-82-2 3-methoxy-4-nitrotoluene 
• 102871-93-2 2-ethoxy-4-methyl-1-nitrobenzene 
• 578-46-1 5-methyl-2-nitroaniline 
• 74-88-4 methyl iodide 
• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 
• 77-78-1 dimethyl sulfate 
• 553-90-2 Dimethyl oxalate 
• 1335201-75-6 C₈H₁₁N₂O₂⁽¹⁺⁾*ClO₄^(1-) 
• 700-38-9 2-nitro-5-methylphenol 
• 343617-23-2 toluene-4-sulfonic acid-(5-methyl-2-nitro-anilide) 

Downstream Products

• 155221-55-9 4-amino-3-(N-methylacetamido)toluene 
• 854624-46-7 5,N,N-trimethyl-2-nitro-aniline 
• 107273-49-4 bis-(2-methyl-4-methylamino-5-nitro-phenyl)-methane 
• 10394-40-8 1,6-dimethylbenzimidazole 
• 131019-87-9 1-amino-4-methyl-2-(N-methylamino)benzene 
• 155221-54-8 3-(N-methylacetamido)-4-nitrotoluene 
• 55783-45-4 3-(methylamino)-4-aminotoluene dihydrochloride salt 
• 857616-83-2 acetic acid-(4-methyl-2-methylamino-anilide) 
• 945023-34-7 1,6-dimethyl-1H-benzimidazol-2-ylamine 
• 29124-66-1 acetic acid-(2-dimethylamino-4-methyl-anilide) 
• 29124-58-1 4,N²,N²-trimethyl-o-phenylenediamine 

Relevant academic research and scientific papers

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

BENZIMIDAZOLE DERIVATIVES AND USES THEREOF

Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

Nitropyridines 11.* recyclization of quaternary nitropyridinium salts into substituted nitroanilines

Substituted nitroanilines have been obtained by the recyclization of nitropyridinium quaternary salts under the action of bases.

BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3/sup

BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3/sup

Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

BENZIMIDAZOLE DERIVATIVES

The present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1,R2, R3, R4, R5, A, X, n, and are as defined herein. Such novel benzamidazole derivatives are useful in trv treatment of abnormal cell growth, such as cancer, in mammals. This invention ate relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing sue compounds.

Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3

High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modification of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors.

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound 1 was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound.

Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-β

2-Arylbenzoxazoles, benzothiazoles and benzimidazoles were identified as new classes of potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase-β (LPAAT-β). Effects of selected inhibitors on proliferation of tumor cells in vitro were investigated.